5 completed. 4 Phase 1, 2 Phase 2.
By phase and status
Follow TNP-2198: new trials by email Literature Review of TNP-2198 trials Research Report on TNP-2198
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
Midazolam, Clarithromycin, TNP-2198 - Helicobacter Pylori Infection | Phase 1 | Completed | TenNor Therapeutics Inc. | 32 | 2024-08-26 | 2024-10-24 |
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection | Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 80 | 2022-06-26 | 2023-12-12 |
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection | Phase 1 / Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 40 | 2021-09-27 | 2023-11-22 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection
TNP-2198, TNP-2198 Placebo - Helicobacter Pylori Infection | Phase 1 | Completed | TenNor Therapeutics (Suzhou) Limited | 48 | 2020-10-20 | 2023-10-13 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants
TNP-2198, TNP-2198 Placebo - Helicobacter Pylori Infection | Phase 1 | Completed | TenNor Therapeutics (Suzhou) Limited | 78 | 2019-05-09 | 2023-10-13 |
Sponsors
TenNor Therapeutics (Suzhou) Limited (4) · TenNor Therapeutics Inc. (1)
Countries
China (5)
Top investigators
Xiaojiao Li (1)
Results publications
PMID 38359854